Non-small cell lung cancer (NSCLC) accounts for approximately 80–85% of lung cancer (3, 4), and approximately 5% of NSCLC tumors harbor anaplastic lymphoma kinase (ALK) gene rearrangements (5, 6). The gene discussed is ALK; the disease is lung cancer.